Importantly, our data shows little measurement variability that could not be accounted for by patient heterogeneity and treatment response, supporting the use 18F-FDG PET as a clinically reliable imaging biomarker for EGFR inhibition in human GBM, which could negate the need for repeat biopsies to confirm pharmacodynamic changes. The gene discussed is EGFR; the disease is glioblastoma.